跳至主要内容
临床试验/DRKS00021259
DRKS00021259招募中未知

The impact of a 12-week open-label placebo treatment on headache days in episodic and chronic migraine: A randomized controlled trial - OLPIMI

niversitätsklinikum EssenKlinik für Neurologie0 个研究点目标入组 150 人开始时间: 2020年10月9日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Age =18 years, history of episodic or chronic migraine (patient self-report and diagnosed by a specialist in neurology according to the International Classification of Headache Disorders (Olesen 2018)) =12 months prior to screening, migraine frequency =4 days per month on average across 3 months prior to screening, consent and fluent German language skills.

排除标准

  • Any substance or alcohol abuse, major depression, schizophrenia, suicidality, hypersensitivity or allergy to any ingredient of the placebo pills, participation in another study using investigational drugs within the last 3 months prior to inclusion, and any acute or chronic pain condition apart from migraine. Patients volunteering to attend the optional MRI session must not suffer from claustrophobia or have any implants or devices unsuitable for MRI.

研究者

发起方
niversitätsklinikum EssenKlinik für Neurologie

相似试验